Literature DB >> 7524759

Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers.

G S Chatta1, T H Price, R C Allen, D C Dale.   

Abstract

Recombinant granulocyte colony stimulating factor (G-CSF) was administered daily for 14 days to healthy young (Y) (20 to 30 years) and elderly (O) (70 to 80 years) volunteers to evaluate the effects of age on the neutrophil (polymorphonuclear leukocytes, PMN) responses. Thirty-eight volunteers were randomized to receive 0 micrograms, 30 micrograms, or 300 micrograms per day. Baseline neutrophil counts (ANC), peak ANCs, and the rate of attaining the peak ANC were similar in both age groups at both doses. The peak ANC was increased 5-fold at 30 micrograms and 15-fold at 300 micrograms in both the young and elderly. Daily tests of PMN function, as measured by an automated chemiluminescence system, showed nearly identical responses to several agonists for both age groups. Marrow proliferative activity as reflected by the percentage of cells in the marrow neutrophil mitotic pool also increased similarly for both age groups at both doses. In contrast, there was an age-related change in blood colony formation as measured by the blood CFU-GM assay. Compared with controls at the 30 micrograms dose, mean colony formation was increased 2-fold in the young versus no change in the elderly and at the 300 micrograms dose 24-fold in the young versus 12-fold in the elderly. These studies indicate that neutrophil responses to rhG-CSF are equivalent in healthy young and elderly volunteers but the mobilization of progenitor cells, as measured by the CFU-GM assay appears to differ substantially.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524759

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Basic pharmacodynamic models for agents that alter production of natural cells.

Authors:  W Krzyzanski; R Ramakrishnan; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

2.  Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

Authors:  B Wang; T M Ludden; E N Cheung; G G Schwab; L K Roskos
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

Review 3.  The role of myelopoietic growth factors in managing cancer in the elderly.

Authors:  Lodovico Balducci; Ignazio Carreca
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Modelling human granulopoiesis under poly-chemotherapy with G-CSF support.

Authors:  M Scholz; C Engel; M Loeffler
Journal:  J Math Biol       Date:  2004-12-20       Impact factor: 2.259

5.  Population balance model of in vivo neutrophil formation following bone marrow rescue therapy.

Authors:  L K Nielsen; J G Bender; W M Miller; E T Papoutsakis
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

6.  A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Authors:  Wenbo Chen; Britton Boras; Tae Sung; Yanke Yu; Jenny Zheng; Diane Wang; Wenyue Hu; Mary E Spilker; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-03-11       Impact factor: 2.745

7.  Efficacy and side effects of granulocyte collection in healthy donors.

Authors:  Franziska Brockmann; Michael Kramer; Martin Bornhäuser; Gerhard Ehninger; Kristina Hölig
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

Review 8.  Neutrophil biology and the next generation of myeloid growth factors.

Authors:  David C Dale
Journal:  J Natl Compr Canc Netw       Date:  2009-01       Impact factor: 11.908

Review 9.  The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.

Authors:  Der-Cherng Liang
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors.

Authors:  G S Chatta; D C Dale
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.